Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Neola Medical AB
NEOLANeola Medical AB (publ) develops medical equipment for continuous monitoring of the lungs of premature babies. It offers neonatal intensive care with NEOLA, a medical device that offer continuous lung monitoring and real-time alerts of life-threatening complications using technology that measures lung volume changes and oxygen gas concentration. NEOLA provides intensive care and healthier lives for preterm born infants. The company was formerly known as GPX Medical AB and changed its name to Neola Medical AB (publ) in June 2022. Neola Medical AB (publ) was incorporated in 2016 and is headquartered in Lund, Sweden. Address: Ideon Science Park, Lund, Sweden, 223 63
Analytics
Zielpreis von Wall Street
31.79 SEKKGV
–Dividendenrendite
–Schlüsselzahlen NEOLA
- Gewinnspanne
- Gesamtumsatz
- Bruttogewinn
- Nettogewinn
Dividenden-Analyse NEOLA
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y>5 - expected 5-9 dividend yield on cost over 10Y<5 - expected <5 dividend yield on cost over 10YMaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
–Ausschüttungsquote 5-Jahres-Durchschnitt
–Verlauf der Dividende NEOLA
- Auszahlungsquote
- Dividends
- Dividendenrendite
Bewertung der Aktie NEOLA
- KUV
- KGV
- Kurs-Buchwert-Verhältnis
- Liquiditätsgrad
- Verschuldungsgrad
Finanzen NEOLA
Ergebnisse | 31.12.2018 | 31.12.2019 | 31.12.2020 | 31.12.2021 | 31.12.2022 | 31.12.2023 | 31.12.2024 | Dynamik | |
Gesamtumsatz | 15 571 437 TRY | 20 870 945 TRY | 422 072 784 TRY | 410 607 496 TRY | 269 143 789 TRY | 344 335 979 TRY | 530 475 043 TRY | ||
Betriebseinnahmen | 1 435 375 TRY | 8 811 847 TRY | 342 717 200 TRY | 309 295 256 TRY | 117 076 849 TRY | -64 069 039 TRY | 17 387 493 TRY | ||
Nettogewinn - (CF) | 864 562 TRY | 7 002 063 TRY | 293 752 670 TRY | 433 857 783 TRY | 330 790 990 TRY | -197 562 616 TRY | -219 141 898 TRY | ||
Normalisiertes Basis-EPS | - | - | 0.07 TRY | 0.10 TRY | 0.08 TRY | -0.02 TRY | -0.03 TRY | ||
Dividende pro Aktie | 0.00 TRY | 0.00 TRY | 0.00 TRY | 0.00 TRY | 1.44 TRY | 0.62 TRY | 0.00 TRY | ||
Auszahlungsquote | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 47.87 % | 168.76 % | 0.00 % | ||
Gesamtvermögen | 19 798 842 TRY | 34 228 311 TRY | 396 236 069 TRY | 860 818 186 TRY | 857 956 026 TRY | 1 354 778 208 TRY | 1 788 900 321 TRY | ||
Gesamtverbindlichkeiten | 10 252 544 TRY | 16 885 139 TRY | 59 814 495 TRY | 34 023 127 TRY | 40 563 659 TRY | 140 053 913 TRY | 235 651 031 TRY | ||
Verschuldungsgrad | 0.52 | 0.49 | 0.15 | 0.04 | 0.05 | 0.10 | 0.13 | ||
Gesamtumlaufvermögen | 10 084 117 TRY | 18 861 868 TRY | 316 627 636 TRY | 708 888 618 TRY | 625 818 247 TRY | 730 611 315 TRY | 759 091 056 TRY | ||
Gesamtverbindlichkeiten | 6 455 349 TRY | 9 831 115 TRY | 54 938 127 TRY | 28 036 949 TRY | 18 439 983 TRY | 46 540 791 TRY | 87 648 655 TRY | ||
Liquiditätsgrad | 1.56 | 1.92 | 5.76 | 25.28 | 33.94 | 15.70 | 8.66 | ||
Schnellliquiditätsgrad | 1.44 | 1.46 | 4.93 | 22.97 | 29.01 | 10.83 | 4.54 | ||
ROA | 4.37 % | 20.46 % | 74.14 % | 50.40 % | 38.56 % | -14.58 % | -12.25 % | ||
FFO-Zinsdeckung | - | - | 146.51 | 149.21 | 97.61 | - | - | ||
KGV - P/E (LTM) | - | - | - | 21.13 | 29.11 | -17.83 | -13.35 | ||
Dividendenrendite (LTM) | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 1.64 % | 3.86 % | 0.00 % | ||
Rückkaufrendite (LTM) | - | -100.00 % | 50.00 % | - | - | -100.00 % | -100.00 % * |